Indeed, the company is aiming to grow revenue to $80bn by 2030. To put this in perspective, total sales amounted to just under $46bn in 2023. If this long-term target is met, it would represent an annualised growth rate in excess of 8pc over the next seven years. This may not appear to be hugely impressive at first glance. But when viewed alongside the company’s defensive credentials, it means the stock offers a highly favourable risk/reward opportunity at what remains an uncertain juncture for investors.
Certainly, falling inflation and interest rate cuts are set to have a positive impact on equity markets over the coming years. But heightened geopolitical risks as well as increasingly generous valuations following the stock market’s recent rise mean that AstraZeneca’s mix of strong growth potential and its relative lack of cyclicality could prove highly attractive in the near term.
This…
